Take this short benchmark to assess how much you would benefit from the course on FDA’s proposed reclassification of Immunohistochemistry (IHC) test systems for oncology therapeutic products (from Class III PMA to Class II with special controls and 510(k)).
This quick check helps you gauge your grasp of why the change is being proposed, who it affects, and what trade-offs it creates—speed vs. rigor, innovation vs. consistency, equity vs. access. It is not an exam; it’s a readiness snapshot.
After this benchmark, you will:
- See where your understanding is strong—and where the course can close gaps on policy intent, operational impact, and risk mitigation.
- Decide if you (or your team) need deeper guidance on special controls, labeling, PCCPs, and the PMA → 510(k) shift.
- Know how this proposal could affect patients, clinicians, labs, and manufacturers—and your next steps.
Who benefits most from taking the full course?
- Teams building, validating, or using oncology IHC assays (manufacturers, labs, clinical leaders).
- Regulatory, quality, and medical affairs professionals navigating 510(k) strategy and special controls.
- Stakeholders planning to submit informed comments during the public rulemaking process.
Time: ~5–7 minutes. No prep needed.



